AstraZeneca’s SECURE Study Targets Real-World Tagrisso Persistence in China

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.

AstraZeneca’s new SECURE study, officially titled “Cross-sectional Qualitative Study to Identify Barriers and Facilitators of Persistence With 3rd Generation EGFR-TKI Osimertinib as Adjuvant Treatment,” aims to understand why early-stage lung cancer patients in China stay on or stop taking Tagrisso. It focuses on real-world behavior, which can shape how well the drug performs outside controlled trials.

The study looks at adjuvant use of osimertinib, a third-generation EGFR-targeted pill sold as Tagrisso and already a key growth driver for AstraZeneca. The goal is not to test the drug’s biology again, but to learn how patients and doctors manage long-term treatment and what helps or hurts persistence in routine practice.

This is an observational, cross-sectional study that only gathers information and does not assign any treatment. Researchers will interview about 85 patients and 15 physicians, using a structured guide, to map out practical barriers and support factors that affect how consistently patients stay on osimertinib.

There is no randomization or masking because the study does not compare drugs or doses. It uses a cohort-style snapshot design, with interviews conducted in waves and then analyzed, so the main purpose is descriptive insight that can guide patient support, not to prove efficacy or safety.

The study was first submitted on April 14, 2026, signaling AstraZeneca’s recent push to deepen its understanding of Tagrisso usage in China. The latest update on May 13, 2026, shows active preparation, although recruiting has not yet started and no results have been filed.

Primary and final completion dates have not been posted, which is typical for a non-interventional project at this early stage. Investors should expect insights, rather than headline trial readouts, to emerge later, feeding into commercial strategy and possibly regional label or reimbursement discussions.

For investors, the study underlines AstraZeneca’s intent to protect and expand Tagrisso’s adjuvant lung cancer franchise, especially in the large Chinese market. Better persistence can translate into longer treatment durations per patient, supporting revenue and reinforcing AZN’s lead over rivals in EGFR-positive non-small cell lung cancer.

Competitors in targeted lung cancer, such as Roche and emerging EGFR-focused biotech players, may be slower to generate this kind of behavioral data at scale. While the update is not a near-term price catalyst, it is a constructive signal on lifecycle management and may support steady confidence in AZN’s oncology growth story.

The SECURE study is not yet recruiting but remains an active, updated project, with further details available on the ClinicalTrials portal.

To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.